COVID-19 Vaccines: Science vs. Anti-Science

Globally, we are seeing a mixed picture of vaccinating the United States and the world against COVID-19, with tremendous progress containing the B.1.1.7 variant in the United States but failing to control widespread transmission in Africa and Latin America. Dr. Hotez will discuss the progress made to date with the US vaccination program, what we can expect toward the end of 2021 and into 2022, and how we can advance vaccinations globally. This session will also explore the impact of a rising and shifting anti-vaccine movement.

Learning Objectives

  • Summarize the impact of the B.1.1.7 variant on US transmission of COVID-19
  • Report on the efficacy and strengths and weaknesses of each of the COVID-19 vaccines in the US vaccination program
  • Discuss global failures or weaknesses in vaccinating low- and middle-income countries, especially in Latin America and Africa
  • Highlight rising anti-vaccine sentiments and its recent shifts
  • Create awareness on approaches to countering anti-vaccine activities

Additional Information

Partner: 
Pri-Med
State Relevance: 
Alabama
Connecticut
Hawaii
Idaho
Illinois
Indiana
Kentucky
Montana
Nebraska
New Hampshire
North Dakota
Pennsylvania
South Carolina
Texas
Virginia
West Virginia
Course summary
Available credit: 
  • 1.00 AANP Contact Hours
    • 0.40 Pharmacology
  • 0.40 AANP Pharmacology Contact Hours
  • 1.00 MOC
  • 1.00 AMA PRA Category 1 Credit
Course opens: 
06/11/2021
Course expires: 
06/11/2022
Rating: 
0

Peter J. Hotez, MD, PhD

Dean, National School of Tropical Medicine 
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine
Health Policy Scholar
Baylor College of Medicine
Houston, TX

Disclosures

The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.

Peter J. Hotez, MD, PhD:  No relevant financial relationships disclosed.  

Richard J. Hamill, MD (moderator): No relevant financial relationships disclosed. 

Baylor College of Medicine has a license for vaccine technology with Biological E. Limited and Dynavax Technologies Corporation.

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and Baylor College of Medicine. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.

Designation Statement

This activity is approved for 1.00 contact hour of continuing education, which includes 0.40 hour of pharmacology.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Obtaining Credit

Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 2 out of the 3 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen. For PAs, the NCCPA accepts for Category 1 CME credit activities designated for AMA PRA Category 1 Credit.

 

Available Credit

  • 1.00 AANP Contact Hours
    • 0.40 Pharmacology
  • 0.40 AANP Pharmacology Contact Hours
  • 1.00 MOC
  • 1.00 AMA PRA Category 1 Credit
Please login or register to take this course.

This course is offered through Pri-Med. 

To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity. 

Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!

Topics

COVID-19 VaccinePharmacotherapeutics, Pharmacology